Cello Group plc (LON:CLL)‘s stock had its “buy” rating reiterated by equities researchers at FinnCap in a research note issued to investors on Tuesday, StockTargetPrices.com reports. They presently have a GBX 132 ($1.72) target price on the stock. FinnCap’s target price indicates a potential upside of 21.66% from the stock’s previous close.

Several other equities analysts have also commented on the company. N+1 Singer reiterated a “buy” rating and issued a GBX 128 ($1.67) target price (up from GBX 127 ($1.66)) on shares of Cello Group plc in a research note on Tuesday, September 20th. Cenkos Securities Ltd reissued a “buy” rating on shares of Cello Group plc in a research report on Wednesday, September 14th. Finally, Peel Hunt reissued a “buy” rating and set a GBX 130 ($1.70) price target on shares of Cello Group plc in a research report on Tuesday, July 26th. Five analysts have rated the stock with a buy rating, Cello Group plc presently has a consensus rating of “Buy” and an average price target of GBX 123.75 ($1.62).

Analyst Recommendations for Cello Group plc (LON:CLL)

Shares of Cello Group plc (LON:CLL) opened at 108.50 on Tuesday. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00. The firm’s market cap is GBX 94.19 million. The stock’s 50 day moving average price is GBX 106.04 and its 200 day moving average price is GBX 98.94.

The company also recently declared a dividend, which will be paid on Friday, November 4th. Shareholders of record on Thursday, October 6th will be given a dividend of GBX 1 ($0.01) per share. This represents a yield of 0.94%. The ex-dividend date is Thursday, October 6th.

About Cello Group plc

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Stock Target Prices

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.